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This review assesses the evidence on the independent risk of cardiovascular events associated with positive Chagas serology.
Methods
We searched for studies using the following outcomes: death, stroke, new onset heart failure, heart failure hospitalization or evidence of left ventricular dysfunction. Studies comparing patients with positive serology for Chagas with a control group with a follow-up longer than 1 year were selected. The Medline, Lilacs and Embase databases were searched on 21 January 2011 without restrictions.
Results
From 5236 potentially relevant studies, 25 fulfilled the inclusion criteria.
Fourteen included patients with heart failure, six with severe symptoms and nine with mild symptoms or asymptomatic patients with low ejection fraction. In four studies of patients in functional class III or IV and in three studies of patients with mild symptoms, a higher risk of death was reported among those with positive serology for Chagas.
Of the 11 studies of patients without symptoms or low ejection fraction, 3 showed a higher risk of mortality related to Chagas exposure. Two of these were based on the same cohort of people aged 460 years.
Overall, 8 out of the 14 heart failure studies and 2 out of the 11 heart damage studies adjusted for confounding factors.
Introduction
Chagas disease is a public health problem that mostly affects poor rural populations in Latin America. 1 However, a gradual increase in positive serology for Chagas is now being observed in non-endemic urban areas as a consequence of high rural to urban migration. 2 Chagas has also been raised as a concern in non-endemic countries as a result of international migration. 3 Chagas disease is caused by the parasite Trypanosoma cruzi. It is most commonly transmitted to humans through the faeces of haematophagous insects of the sub-family Triatomine, including Triatoma infestans and Rhodnius prolixus. Chagas can also be transmitted congenitally, through transfusions, and occasionally via oral contamination, although these account for a small minority of cases. 4 The disease has two clinical phases: (i) an acute phase that is usually self-limited and asymptomatic in 95% of patients 4 and (ii) a chronic phase, with a lengthy latency period of 10-30 years, where a percentage of infected individuals develop signs or symptoms consistent with cardiomyopathy. 1, 4, 5 However, it is important to note that appropriate cohort studies specifically designed to determine the percentage of seropositive patients who will develop cardiomyopathy have not been published. Although widely cited, the estimate that 20-30% of seropositive individuals will go on to develop cardiomyopathy is therefore questionable. [5] [6] [7] Chronic Chagas cardiomyopathy has been described as the most common cause of non-ischaemic cardiomyopathy worldwide. 8 However, a consensus does not exist regarding the actual risk of cardiomyopathy and other cardiovascular events associated with positive Chagas serology independent of the confounding effect of poverty. Socio-economic status is associated with multiple confounding factors that can also increase the risk of developing cardiovascular events. Indeed, there is evidence of an association between poverty and heart failure. [9] [10] [11] The associations between socio-economic status and the risk factors of heart failure and cardiovascular events, such as heart disease, 12, 13 poor access to risk factors treatment, [14] [15] [16] [17] tobacco consumption 18 or alcohol intake, 19, 20 are also well documented. This systematic review aims to assess the evidence base on the independent risk of cardiovascular events associated with positive Chagas serology.
Methods
We searched the literature for studies comparing patients with positive serology for Chagas with a control group. To be included, a study needed to have a follow-up period 41 year and must have included at least one of the following end points: death, strokes, hospitalizations due to heart failure or development of myocardial injury evidenced by impaired ventricular function assessed by diagnostic imaging techniques.
The damage measured by electrocardiographic examinations was not considered because no specific electrocardiographic alteration demonstrated consistently prognostic value. 21 Studies that met the above-mentioned criteria were considered eligible, regardless of their design, whether published and the language in which they were written. Studies that assessed the prognosis of positive serology for Chagas disease in patients treated with devices (re-synchronization therapy or implantable cardioverter-defibrillator), invasive surgical procedures (cardiomyoplasty or ventricular remodelling surgery) or cardiac transplantation were excluded. We searched for studies across three databases without language restrictions: Medline (1946-2011), Lilacs (1986-2011) and EMBASE . We also consulted renowned Latin American experts to obtain unpublished information. All the titles and abstracts were assessed by two independent investigators (B.L., J.K.), who eliminated those studies that did not meet the inclusion criteria. Disagreements were resolved by consensus, and in the case of persistent dissent, the full text of the article was examined.
The full text of studies meeting the inclusion criteria was analysed by two reviewers who extracted the following points:
General description of the study: Years of field work and publication, country of origin, whether the included participants suffered from heart damage and how it was defined, whether they were hospitalized and whether the sample was drawn from urban or rural areas. Patient data: Number of Chagasic and non-Chagasic subjects, along with description of these groups (age, sex and blood pressure). End points: How the risk of experiencing each end point was reported, comparing Chagasic and non-Chagasic groups (odds ratios, hazard ratios, relative risk, b coefficients, confidence intervals or standard errors, number of events and P value), and whether an adjustment by statistical methods was performed (and if so, which variables were used). Study quality 23, 24 : Sampling method (probabilistic or using consecutive patients), along with whether it included a sample size calculation, a clear description of the inclusion and exclusion criteria, explanation of the follow-up method and the number of individuals lost in follow-up, adequate measurement of exposure to Chagas (two positive serologies by different methods as it is recommended today) 25 and the events (how were the events defined and whether they were properly measured), confounding control through statistical methods and statistical analysis (missing data management and loss to follow-up, time-to-event analysis).
Results

Search
On 21 January, 2011, a search of Medline, Lilacs and Embase was carried out, finding a total of 5236 articles. After removing duplicated articles, 3617 articles were left for the screening of titles and abstracts. In this step, 3546 articles were deemed irrelevant, leaving 71 articles for a complete reading, although one of them could not be found. 26 After reading, another 45 articles were eliminated, yielding a final set of 25 articles ( Figure 1 ). Table 1 summarizes the studies included in this review. The studies were classified according to the clinical condition of subjects included in it. In 14 studies, the patients had heart failure or impaired ventricular function assessed by diagnostic imaging techniques. Six of these studies [27] [28] [29] [30] [31] [32] assessed patients with advanced heart failure (functional class III or IV), and nine studies included patients with mild symptoms or those who were asymptomatic but with an impaired ejection fraction. 30, [33] [34] [35] [36] [37] [38] [39] [40] Heringer et al.'s 30 publication included both types of patients; thus, it is considered in both sets of conditions. Eleven studies included patients without heart failure or impaired ventricular function assessed by diagnostic imaging techniques. 6, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Only 1 of the 14 studies that evaluated patients with heart failure was published before year 2000, 34 whereas studies involving individuals without heart failure were mostly published before that date. 6, [41] [42] [43] [46] [47] [48] [49] [50] Most of the studies were conducted in Brazil, except for three studies that were conducted in Chile, 41 Venezuela 49 and the United States. 40 Most of the studies were published in journals, whereas three studies were only presented as abstracts in conferences/meetings. 37, 38, 40 We did not find any unpublished sources.
Description of studies
Most of the studies identified were self-described as cohort studies. The majority of these were prospective, 6, 27, 31, [33] [34] [35] [36] [37] [38] [39] [40] 42, [44] [45] [46] two were referred to as retrospective 30, 43 and in three of the studies, it was not specified whether the follow-up was prospective. 28, 29, 32 Four studies were self-described as repeated surveys and not as a formal cohort. 41, 47, 48, 50 Study results Table 2 describes the number of patients included with and without Chagas and their demographic characteristics along with the main results of each study. Most of the studies describe the results in terms of death, with only four studies using other end points such as hospital admissions, 37, 40, 51 development of heart failure symptoms or ventricular dysfunction 6, 44 and death due to stroke. 44 Studies in patients with advanced heart failure In four out of six studies that included patients with functional class III or IV heart failure, a higher risk of Both are included because they report different end point. c It also included heart failure or low LVEF. It only included the groups that have a comparative group with negative serology and includes all the patients in whom a myocardial biopsy was performed during the study years. HF, heart failure; LVEF, Left ventricle ejection fraction; FC, functional class; LVDD/BS, left ventricular diastolic diameter/body surface. CARDIOVASCULAR EVENTS AND CHAGAS DISEASE death in patients with positive serology was reported, adjusted only by clinical variables. 27, 28, 31, 32 One of the remaining studies did not report whether the risk was increased, 30 whereas the other one reported a high risk in the univariable analysis, but not in the multivariable analysis. 29 None of these studies adjusted for socio-economic status or poverty.
Studies in patients with heart failure with mild or no symptoms and with impaired ejection fraction In three out of nine studies with patients with impaired ventricular function or heart failure with mild symptoms, a higher risk of death was observed in the population exposed to Chagas. 34, 36, 39 In three other studies, no differences were found 33, 35, 37 (one of them, only after adjusting for education level). 35 On the other hand, two studies did not report the results of a statistical test and present non-conclusive results based on small samples. 30, 38 Only one study assessed the risk of hospitalization in this sub-group, detecting an increased risk for subjects with positive serology. 40 Only two studies of this group of patients performed an adjustment through a multivariable analysis, one analysis per educational level, 35 and the other through multiple clinical, electrocardiographic, radiological and echocardiographic variables. 36 Studies in asymptomatic patients without demonstrated impaired ejection fraction Studies that evaluated subjects without heart failure or impaired ventricular function, as assessed by diagnostic imaging techniques, also showed mixed results. Among these studies, only three showed a higher risk of cardiovascular events among patients with positive serology for Chagas. Lima Costa's studies, 44, 45 both of which focus on patients aged 560 years, show an increase in total and stroke mortality among patients with a positive serology for Chagas in a follow-up of 10 years, after adjusting by factors such as sex, age, education and number of risk factors. Arribada et al.'s 41 study showed a greater crude mortality rate in patients with altered electrocardiography (7.7% for patients with Chagas and 2.2% for control subjects) after a 4-year period. In the other studies of this sub-group, statistical tests were not reported, except for studies by Maguire et al. 46 and Pimenta et al., 42 where patients with positive serology were not found to experience a higher risk of mortality.
Quality assessment
Only one study that examined advanced heart failure 32 and two studies that included patients with mild symptoms or with impaired ventricular dysfunction 35, 39 reported data on patient attrition. On the other hand, in most of the studies with asymptomatic subjects, these data were described. 6, 41, 43, 44, 46, 48, 50 The loss to follow-up rate in this sub-group reached values of up to 44.8%, and in some studies, the loss to follow-up was different in populations with and without positive serology for Chagas 6, 41, 43, 50 (Table 3) . Of the 14 studies that included patients with heart failure, 9 explicitly described their patient inclusion and exclusion criteria, and a total of 8 described their method of selecting patients. None of the studies used a probabilistic sampling strategy, although six studies described sampling consecutive patients. Moreover, only 5 of 11 studies with patients without heart failure or impaired ventricular function described inclusion and exclusion criteria and the process used for their selection. Four studies were based on community censuses, and one study was based on consecutive patients (Table 3) .
A majority of studies (16 out of 25) used two different techniques to measure Chagas exposure, whereas two used one technique, and seven did not state how they carried out their diagnosis. In most of the studies, the events were correctly assessed, and only one study reported them wrongly because they included deaths together with subjects lost to followup 43 (Table 3) . Time-to-event analysis was used in a majority of studies (14 out of 25), with articles presenting survival curves or tests such as Cox regression. Only a small number of studies presented discussion of how patient attrition was managed in the analysis or whether missing data were imputed, 2,3 and only two studies described a sample size calculation (Table 3) .
Statistical adjustment through a multivariable analysis was carried out in five of six studies of patients with advanced heart failure and in three of nine studies of patients with heart failure in earlier stages. The adjustment variables were mainly clinical, except one study that included the educational level of the subjects. 35 Among patients without heart failure, only the studies of Lima Costa et al. 44, 45 carried out a multivariable analysis, and these adjusted for sex, age, educational level and the presence of other risk factors (Table 3 ).
Discussion
The analysis of studies that compare groups with positive and negative serology for Chagas shows that seropositive patients experience an elevated risk of death, mainly when considering patients with advanced stage heart failure. However, the evidence is not conclusive when considering patients with early stage heart failure, and even less in subjects without evident heart disease. 45 In addition, the risk of experiencing events such as stroke and/or development or hospitalization due to heart failure was evaluated among seropositive patients in only very few studies. 6, 37, 40, 44 This systematic review reveals that few studies of subjects without heart failure included appropriate confounding factors through multivariable analysis. This is particularly problematic, as Chagas disease is 
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Studies that included patients with heart failure in functional class III or IV De Campos CARDIOVASCULAR EVENTS AND CHAGAS DISEASE strongly related to poverty. To estimate the real risk associated with the infection, the assessment of the effect of multiple confounding factors is needed because those may increase the risk of cardiomyopathy in vulnerable groups. Only the studies by Lima Costa et al. 44, 45 that included elderly subjects, adjusted for socio-economic status through level of education.
The association between presenting positive serology for Chagas and the risk of cardiovascular events seems to be more conclusive in patients with heart failure in functional class III or IV. Indeed, a positive serology for Chagas was associated with an increase in mortality within this sub-group in most of the studies included in this review. A number of factors associated with Chagas disease may explain this effect, including a higher frequency of ventricular arrhythmias, as well as the risk associated with right ventricular dysfunction, extensive myocardial damage, dysfunction of the autonomous nervous system and social deprivation. 31, 32 These results suggest the need for well-designed observational studies of subjects without heart failure. Such studies should include a long-term follow-up and a sample size large enough to enable detection of not only the risk of death but also the risk of developing other cardiovascular events in subjects with positive serology compared with those not exposed to Chagas disease. In this context, the Prospective Urban Rural Epidemiology study 52 is carrying out a 10-year follow-up of urban and rural populations with and without positive serology for Chagas; this will enable researchers not only to assess the risk of the different end points checked for this review but also to make the necessary adjustment for confounding factors associated with poverty.
A lack of evidence of the risk for cardiovascular events in subjects without heart failure has implications both for the population with positive serology and from a public health perspective. It may diminish the unfair stigmatization of seropositive patients as 'Chagasic'. It is currently a common practice in many endemic countries to ask for serology tests as pre-employment medical examinations, an obvious discrimination of seropositive patients. 53 Our findings increase new challenges for public health, including the need to determine the independent risk of cardiovascular events associated with chronic Chagas infection, to establish, in a rigorous manner, the true burden of this disease. Such knowledge is needed to develop evidence-based public health policies.
Future research should seek to identify the poverty-related factors that increase the risk of cardiovascular events among seropositive patients. Identification of those factors may be crucial to the development of strategies to prevent disease progression.
The results of this review should be considered cautiously, taking into account the quality of the studies, particularly that of studies that included subjects without heart failure that were mostly performed with limited methodology. Many studies in this literature used an insufficient sample size and lacked a sample size calculation. Many studies also experienced high rates of attrition and failed to adequately discuss it. Perhaps most importantly, almost all of the studies in this review failed to include confounding factors, which would have allowed the establishment of the independent effect of the positive serology in the risk of cardiovascular events.
Conclusion
This review demonstrates a higher risk of death in patients with advanced heart failure and positive serology for Chagas. However, the results should be considered cautiously, taking into account the quality of the studies. The evidence of a higher mortality in subjects without cardiomyopathy is weak, and in relation to other events such as stroke or heart failure development or hospitalizations, the evidence is null.
Well-designed observational studies of subjects with positive serology for Chagas are needed to determine the risk of cardiovascular events associated with this disease, after adjusting for the multiple confounding factors associated with poverty.
Further epidemiological studies are needed that include an appropriate methodology to determine the true independent risk associated with positive serology for Chagas. These studies should include not only death but also other cardiovascular end points such as development of heart failure symptoms, ventricular dysfunction and stroke.
